APA (7th ed.) Citation

Richter, J., Lee, H. C., Jagannath, S., Zonder, J. A., Hoffman, J. E., Zhou, Z., . . . Bumma, N. (2026). Linvoseltamab versus elranatamab for triple-class exposed relapsed or refractory multiple myeloma: An indirect treatment comparison. Leukemia & Lymphoma, 1. https://doi.org/10.1080/10428194.2026.2688561

Chicago Style (17th ed.) Citation

Richter, Joshua, et al. "Linvoseltamab Versus Elranatamab for Triple-class Exposed Relapsed or Refractory Multiple Myeloma: An Indirect Treatment Comparison." Leukemia & Lymphoma 2026: 1. https://doi.org/10.1080/10428194.2026.2688561.

MLA (9th ed.) Citation

Richter, Joshua, et al. "Linvoseltamab Versus Elranatamab for Triple-class Exposed Relapsed or Refractory Multiple Myeloma: An Indirect Treatment Comparison." Leukemia & Lymphoma, 2026, p. 1, https://doi.org/10.1080/10428194.2026.2688561.